Oxford Biomedica......the next level !!!!

Istykhan, I am not aware of any share magazine or fund manager putting OXB on their "shopping lists for the new year".

Alizyme expect to out-license three drugs during 2004 (COLAL-PRED, ATL-962 and Renzapride) and one during 2005 (ATL-104). Three of AZM's drugs have completed PIIb and one is in PIIa. Conversely, Oxford Biomedica (if very lucky) may out-license Trovax around the end of 2004 or in H1 2005 (12 to 18 months from now). The rest of OXB's pipeline is early stage or pre-climical, and all is high-risk. Alizyme is the better short-term investment of the two imo. (Incidentally, Framlington have just increased their stake in AZM).